Contact lens and contact lens product

Abstract

The invention provides a contact lens and a contact lens product. The composition of the contact lens comprises a humectant. The moisturizing agent comprises a glucan, and the glucan in the composition of the contact lens comprises 1-3 / 1-6-glucan or Beta-glucan. Therefore, the moisture loss of the contact lens to the air can be reduced, and the moisture retention degree of the contact lens can be improved.

Description

Technical Field

[0001] The present disclosure relates to a contact lens and a contact lens product, and more particularly to a contact lens and a contact lens product having excellent moisture retention. Background Art

[0002] Contact lenses have different fixed water contents depending on their material compositions. When a user wears a contact lens, the moisture on the surface of the eyeball will be absorbed by the contact lens to replenish the moisture lost by the contact lens to the air, and the moisture loss will increase with the wearing time. Therefore, when a user wears a contact lens for a long time, discomfort symptoms such as redness, swelling, and heat may occur due to dry eyes. To improve the comfort of the user during long-term wearing and increase the user's willingness to purchase contact lens products, it is necessary to effectively reduce the moisture loss of the contact lens. Summary of the Invention

[0003] The present disclosure provides a contact lens and a contact lens product, which use dextran with high moisturizing effect as a moisturizer in the contact lens, can reduce the moisture loss of the contact lens to the air, and helps to improve the moisture retention of the contact lens.

[0004] According to an embodiment of the present disclosure, a contact lens is provided. The composition of the contact lens includes a moisturizer. The moisturizer includes a dextran, and the dextran in the composition of the contact lens includes 1-3 / 1-6-dextran. The weight percentage of dextran in the composition of the contact lens is Pc, and the average transmittance of the contact lens at 400 nm to 700 nm is T4070, which satisfies the following conditions: 0.001% ≤ Pc ≤ 1.00%; and 90% ≤ T4070.

[0005] According to another embodiment of the present disclosure, a contact lens product is provided, which includes the contact lens described in the previous paragraph and a buffer solution. The contact lens is immersed in the buffer solution.

[0006] According to another embodiment of the present disclosure, a contact lens is provided. The composition of the contact lens includes a moisturizer. The moisturizer includes a dextran, and the dextran in the composition of the contact lens includes Beta-dextran. The weight percentage of dextran in the composition of the contact lens is Pc, and the average transmittance of the contact lens at 450 nm to 630 nm is T4563, which satisfies the following conditions: 0.0001% ≤ Pc; and 90% ≤ T4563.

[0007] According to another embodiment of the present disclosure, a contact lens product is provided, which includes the contact lens described in the previous paragraph.

[0008] According to another embodiment of the present disclosure, a contact lens product is provided, which includes a contact lens and a buffer solution. The contact lens is immersed in the buffer solution. The buffer solution contains a humectant, the humectant of the buffer solution contains a dextran, and the dextran in the buffer solution contains Beta-dextran. The weight percentage of dextran in the buffer solution is Pb, which satisfies the following conditions: 0.0001% ≤ Pb ≤ 5.00%. BRIEF DESCRIPTION OF THE DRAWINGS

[0009] None DETAILED DESCRIPTION

[0010] An embodiment of the present disclosure provides a contact lens, and the composition of the contact lens contains a humectant. The humectant contains a dextran, and the dextran in the composition of the contact lens contains 1-3 / 1-6-dextran. Thereby, using dextran with a high moisturizing effect as the humectant of the contact lens reduces the water loss of the contact lens into the air, which helps to improve the moisture retention of the contact lens. Furthermore, Ganoderma lucidum achieves water preservation with highly moisturizing 1-3 / 1-6-dextran, and by selecting 1-3 / 1-6-dextran rich in Ganoderma lucidum as the contact lens humectant, it helps to maximize the moisture retention of the contact lens.

[0011] Another embodiment of the present disclosure provides a contact lens, and the composition of the contact lens contains a humectant. The humectant contains a dextran, and the dextran in the composition of the contact lens contains Beta-dextran. Thereby, using dextran with a high moisturizing effect as the contact lens humectant reduces the water loss of the contact lens into the air, which helps to improve the moisture retention of the contact lens. Furthermore, selecting Beta-dextran as the humectant of the contact lens helps to further improve the moisture retention of the contact lens.

[0012] For the contact lens according to the present disclosure, the weight percentage of dextran in the composition of the contact lens is Pc, which can satisfy the following conditions: 0.001% ≤ Pc ≤ 1.00%. By restricting the weight percentage of dextran in the composition of the contact lens, the contact lens has both high moisture retention and high visible light transmittance. Or, it can satisfy the following conditions: 0.0001% ≤ Pc ≤ 10.00%. Or, it can satisfy the following conditions: 0.0005% ≤ Pc ≤ 5.00%. Or, it can satisfy the following conditions: 0.003% ≤ Pc ≤ 0.10%. Or, it can satisfy the following conditions: 0.005% ≤ Pc ≤ 0.05%. Or, it can satisfy the following conditions: 0.006% ≤ Pc ≤ 0.02%. Or, it can satisfy the following conditions: 0.008% ≤ Pc ≤ 0.013%. Or, it can satisfy the following conditions: 0.0001% ≤ Pc.

[0013] The contact lens according to the present disclosure has an average transmittance of T4070 at 400 nm to 700 nm, which can satisfy the following conditions: 90% ≤ T4070. By satisfying the average transmittance at 400 nm to 700 nm, the contact lens maintains a high transmittance of overall visible light. Alternatively, it can satisfy the following conditions: 90.5% ≤ T4070. Alternatively, it can satisfy the following conditions: 91% ≤ T4070. Alternatively, it can satisfy the following conditions: 91.5% ≤ T4070. Alternatively, it can satisfy the following conditions: 92% ≤ T4070. Alternatively, it can satisfy the following conditions: 92.5% ≤ T4070 ≤ 100%.

[0014] The contact lens according to the present disclosure has an average transmittance of T4563 at 450 nm to 630 nm, which can satisfy the following conditions: 90% ≤ T4563. By satisfying the average transmittance at 450 nm to 630 nm, the contact lens maintains a high transmittance of visible light in a specific wavelength band. Alternatively, it can satisfy the following conditions: 90.5% ≤ T4563. Alternatively, it can satisfy the following conditions: 91% ≤ T4563. Alternatively, it can satisfy the following conditions: 91.5% ≤ T4563. Alternatively, it can satisfy the following conditions: 92% ≤ T4563. Alternatively, it can satisfy the following conditions: 92.5% ≤ T4563 ≤ 100%.

[0015] The contact lens according to the present disclosure has a molecular weight of MWc for dextran in the composition of the contact lens, which can satisfy the following conditions: 10 kDa ≤ MWc ≤ 2000 kDa. By adding dextran with an appropriate molecular weight to the contact lens, it is possible to prevent dextran from interfering with visible light penetration and improve the physical strength of the contact lens, which helps to maintain the penetration effect of the contact lens and helps to stabilize the structure of the contact lens. Alternatively, it can satisfy the following conditions: 30 kDa ≤ MWc ≤ 1800 kDa. Alternatively, it can satisfy the following conditions: 50 kDa ≤ MWc ≤ 1500 kDa. Alternatively, it can satisfy the following conditions: 100 kDa ≤ MWc ≤ 1000 kDa. Alternatively, it can satisfy the following conditions: 150 kDa ≤ MWc ≤ 700 kDa.

[0016] For the contact lens according to the present disclosure, the molecular particle size of dextran in the composition of the contact lens is PSc, which can satisfy the following conditions: 50 nm ≤ PSc ≤ 5000 nm. By adding dextran with an appropriate molecular particle size to the contact lens, the dextran can be effectively embedded in the polymer network structure and the loss of dextran can be reduced, which helps to improve the moisturizing time effect of the contact lens. Alternatively, it can satisfy the following conditions: 500 nm ≤ PSc ≤ 4000 nm. Alternatively, it can satisfy the following conditions: 1000 nm ≤ PSc ≤ 3000 nm. Alternatively, it can satisfy the following conditions: 1200 nm ≤ PSc ≤ 2500 nm. Alternatively, it can satisfy the following conditions: 1500 nm ≤ PSc ≤ 2300 nm. Alternatively, it can satisfy the following conditions: 1600 nm ≤ PSc ≤ 2100 nm.

[0017] For the contact lens according to the present disclosure, the diameter of the contact lens is Dc, which can satisfy the following conditions: 13.8 mm ≤ Dc ≤ 14.5 mm. By designing an appropriate contact lens diameter, it is possible to avoid lens drift caused by too small a diameter and corneal deformation caused by too large a diameter, which helps to improve the wearing stability of the user. Alternatively, it can satisfy the following conditions: 13 mm ≤ Dc ≤ 15 mm. Alternatively, it can satisfy the following conditions: 13.5 mm ≤ Dc ≤ 14.8 mm. Alternatively, it can satisfy the following conditions: 14.0 mm ≤ Dc ≤ 14.2 mm.

[0018] For the contact lens according to the present disclosure, the Beta-dextran in the composition of the contact lens may include 1-3 / 1-6-dextran. Ganoderma lucidum achieves water preservation with highly moisturizing 1-3 / 1-6-dextran, and by selecting the 1-3 / 1-6-dextran rich in Ganoderma lucidum as the contact lens moisturizer, it helps to maximize the moisture retention of the contact lens.

[0019] For the contact lens according to the present disclosure, the contact lens may be a hydrogel contact lens, and a main monomer of the contact lens may be 2-hydroxyethyl methacrylate. By using dextran in a hydrogel contact lens with 2-hydroxyethyl methacrylate as the main monomer, it helps to improve the wearing comfort of the hydrogel contact lens.

[0020] For the contact lens according to the present disclosure, the composition of the contact lens may further include an ultraviolet light absorber or a blue light absorber, a pigment, a beneficial agent, an antioxidant, and a myopia control agent. By adding an ultraviolet light absorber, a blue light absorber, a beneficial agent, an antioxidant, etc., adverse reactions such as eye damage and inflammation can be reduced, and the discomfort of the contact lens absorbing moisture on the surface of the eyeball can be reduced. Furthermore, by adding a pigment, the aesthetic degree of the contact lens can be increased, thereby increasing the wearing willingness of the user. Furthermore, by adding a myopia control agent, the contact lens has the effect of controlling and delaying the degree of myopia, thereby enhancing the application range of the contact lens.

[0021] Each technical feature in the contact lenses of the present disclosure can be combined and configured to achieve the corresponding effects.

[0022] Another embodiment of the present disclosure provides a contact lens product, including the contact lenses as described in the foregoing embodiment.

[0023] Another embodiment of the present disclosure provides a contact lens product, including the contact lenses as described in the foregoing embodiment and a buffer solution, and the contact lenses are immersed in the buffer solution.

[0024] For the contact lens product according to the present disclosure, the buffer solution may include a humectant. The humectant in the buffer solution may include a dextran, and the dextran in the buffer solution may include Beta-dextran. Using dextran with high moisturizing effect as the humectant in the buffer solution helps to improve the wearing comfort of the contact lenses, and selecting Beta-dextran as the humectant in the buffer solution helps to further improve the wearing comfort of the contact lenses.

[0025] For the contact lens product according to the present disclosure, the weight percentage of dextran in the buffer solution is Pb, which may satisfy the following conditions: 0.0003% ≤ Pb ≤ 1.00%. By restricting the weight percentage of dextran in the buffer solution, it helps to reduce the foreign body sensation when the user places the contact lenses in the eyes. Alternatively, it may satisfy the following conditions: 0.0001% ≤ Pb ≤ 5.00%. Alternatively, it may satisfy the following conditions: 0.0005% ≤ Pb ≤ 0.50%. Alternatively, it may satisfy the following conditions: 0.001% ≤ Pb ≤ 0.30%. Alternatively, it may satisfy the following conditions: 0.003% ≤ Pb ≤ 0.10%. Alternatively, it may satisfy the following conditions: 0.005% ≤ Pb ≤ 0.05%. Alternatively, it may satisfy the following conditions: 0.0055% ≤ Pb ≤ 0.008%.

[0026] For the contact lens product according to the present disclosure, the molecular weight of the dextran in the buffer solution is MWb, which may satisfy the following conditions: 50 kDa ≤ MWb ≤ 1500 kDa. The molecular weight of dextran affects its effect as a humectant, and by adding dextran with an appropriate molecular weight in the buffer solution, it helps to balance the comfort and foreign body sensation when wearing contact lenses. Alternatively, it may satisfy the following conditions: 10 kDa ≤ MWb ≤ 2000 kDa. Alternatively, it may satisfy the following conditions: 30 kDa ≤ MWb ≤ 1800 kDa. Alternatively, it may satisfy the following conditions: 100 kDa ≤ MWb ≤ 1000 kDa. Alternatively, it may satisfy the following conditions: 150 kDa ≤ MWb ≤ 700 kDa.

[0027] For the contact lens product according to the present disclosure, the molecular particle size of dextran in the buffer solution is PSb, which can satisfy the following conditions: 500 nm ≤ PSb ≤ 4000 nm. By adding dextran with an appropriate molecular particle size to the buffer solution, the dextran is uniformly dispersed in the buffer solution, which helps to improve the uniformity of the buffer solution. Alternatively, it can satisfy the following conditions: 50 nm ≤ PSb ≤ 5000 nm. Alternatively, it can satisfy the following conditions: 1000 nm ≤ PSb ≤ 3000 nm. Alternatively, it can satisfy the following conditions: 1200 nm ≤ PSb ≤ 2500 nm. Alternatively, it can satisfy the following conditions: 1500 nm ≤ PSb ≤ 2300 nm. Alternatively, it can satisfy the following conditions: 1600 nm ≤ PSb ≤ 2100 nm.

[0028] For the contact lens product according to the present disclosure, the water content of the contact lens is Cw, which can satisfy the following conditions: 54.5% ≤ Cw. By designing an appropriate water content of the contact lens, the wearing comfort and the moisturizing effect of the contact lens can be balanced. Alternatively, it can satisfy the following conditions: 55.0% ≤ Cw ≤ 100%. Alternatively, it can satisfy the following conditions: 55.5% ≤ Cw ≤ 60.0%.

[0029] For the contact lens product according to the present disclosure, the Beta-dextran in the buffer solution may contain 1-3 / 1-6-dextran. Ganoderma lucidum achieves water preservation with highly moisturizing 1-3 / 1-6-dextran, and by selecting 1-3 / 1-6-dextran rich in Ganoderma lucidum as the moisturizer of the buffer solution, it helps to optimize the wearing comfort of the contact lens.

[0030] For the contact lens product according to the present disclosure, the composition of the contact lens may contain a moisturizer, and the moisturizer of the composition of the contact lens may contain Beta-dextran. Selecting Beta-dextran as the contact lens moisturizer helps to further improve the moisture retention of the contact lens.

[0031] For the contact lens product according to the present disclosure, the viscosity of the buffer solution is VI, which can satisfy the following conditions: VI ≤ 10 Pa·s. By designing an appropriate viscosity of the buffer solution, it is possible to avoid the buffer solution on the surface of the contact lens making it difficult to blink, thereby reducing the discomfort of the user. Alternatively, it can satisfy the following conditions: 0 Pa·s < VI ≤ 5 Pa·s. Alternatively, it can satisfy the following conditions: 0.1 Pa·s ≤ VI ≤ 3 Pa·s. Alternatively, it can satisfy the following conditions: 0.3 Pa·s ≤ VI ≤ 2 Pa·s. Alternatively, it can satisfy the following conditions: 0.5 Pa·s ≤ VI ≤ 1.5 Pa·s. Alternatively, it can satisfy the following conditions: 0.75 Pa·s ≤ VI ≤ 1.25 Pa·s. Alternatively, it can satisfy the following conditions: 0.9 Pa·s ≤ VI ≤ 1.1 Pa·s.

[0032] For the contact lens product according to the present disclosure, the pH value of the buffer solution is pHb, which can satisfy the following conditions: 7.3 ≤ pHb ≤ 7.5. The pH value of the tear fluid is approximately 7.4. By designing the pH value of the buffer solution to be close to that of the tear fluid, the acid-base neutralization between the buffer solution on the contact lens surface and the tear fluid can be avoided, which helps to avoid adverse reactions. Alternatively, it can satisfy the following conditions: 6.5 ≤ pHb ≤ 8. Alternatively, it can satisfy the following conditions: 6.8 ≤ pHb ≤ 7.8. Alternatively, it can satisfy the following conditions: 7.0 ≤ pHb ≤ 7.6. Alternatively, it can satisfy the following conditions: 7.35 ≤ pHb ≤ 7.45.

[0033] For the contact lens product according to the present disclosure, the osmotic pressure of the buffer solution is Ob, which can satisfy the following conditions: 0.280 Osmol / kg·H 2 O ≤ Ob ≤ 0.350 Osmol / kg·H 2 O. By designing an appropriate osmotic pressure of the buffer solution, the dehydration and swelling of the corneal epithelium caused by the buffer solution on the contact lens surface can be avoided, thereby reducing the discomfort of the user. Alternatively, it can satisfy the following conditions: 0.285 Osmol / kg·H 2 O ≤ Ob ≤ 0.340 Osmol / kg·H 2 O. Alternatively, it can satisfy the following conditions: 0.290 Osmol / kg·H 2 O ≤ Ob ≤ 0.320 Osmol / kg·H 2 O. Alternatively, it can satisfy the following conditions: 0.295 Osmol / kg·H 2 O ≤ Ob ≤ 0.305 Osmol / kg·H 2 O.

[0034] Each of the technical features in the above-mentioned contact lens and contact lens product according to the present disclosure can be combined and configured to achieve the corresponding effects.

[0035] The composition of the contact lens described in the present disclosure may include at least one, at least two, at least three, and at least four humectants. The composition of the contact lens may include at least one, at least two, at least three, and at least four monomers. The composition of the contact lens may include at least one, at least two, at least three, and at least four initiators. The composition of the contact lens may include at least one, at least two, at least three, and at least four crosslinking agents. The composition of the contact lens may include at least one, at least two, at least three, and at least four diluents. The composition of the contact lens may optionally include at least one, at least two, at least three, and at least four ultraviolet light absorbers or blue light absorbers. The composition of the contact lens may include at least one, at least two, at least three, and at least four pigments. The composition of the contact lens may include at least one, at least two, at least three, and at least four beneficial agents. The composition of the contact lens may include at least one, at least two, at least three, and at least four antioxidants. The composition of the contact lens may include at least one, at least two, at least three, and at least four myopia control agents. The composition of the contact lens may be located inside or on the surface of the contact lens. When the composition of the contact lens is located inside the contact lens, it means that the composition of the contact lens is used as a material and cured into the contact lens. When the composition of the contact lens is located on the surface of the contact lens, it means that the composition of the contact lens is bonded or attached to the surface of the contact lens by means of coating or soaking, etc.

[0036] The weight percentage of the contact lens composition described in the present disclosure refers to the weight percentage of each composition to the dry contact lens after the contact lens body in the contact lens product is taken out from the buffer solution and completely dehydrated.

[0037] The humectants of the composition of the contact lens described in the present disclosure may include glucan, polyethylene glycol-40 hydrogenated castor oil (PEG 40 Castor Oil), polyethylene glycol-400 (PEG 400), glycerol, allantoin, hyaluronic acid, ceramide, cholesterol, seabuckthorn oil, polyglutamic acid (γ-PGA), trehalose, alginic acid, hydroxypropyl methylcellulose (HPMC), 2-methacryloyloxyethyl phosphorylcholine (MPC; 2-Methacryloyloxyphosphorylcholine), etc., and their salts.

[0038] The dextran in the composition of the contact lens described in this disclosure may have a stereoconfiguration of D-form or L-form. Dextran may include Alpha-dextran and Beta-dextran. Alpha-dextran may include Alpha-1-3-dextran, Alpha-1-4-dextran, Alpha-1-6-dextran, Alpha-1-3 / 1-4-dextran, Alpha-1-4 / 1-6-dextran, and Alpha-1-3 / 1-6-dextran, where the main chain of Alpha-dextran may be bonded by 1,3, 1,4, or 1,6, and the side chain of Alpha-dextran may be bonded by 1,3, 1,4, or 1,6. Beta-dextran may include Beta-1-3-dextran, Beta-1-4-dextran, Beta-1-6-dextran, Beta-1-3 / 1-4-dextran, Beta-1-4 / 1-6-dextran, and Beta-1-3 / 1-6-dextran, where the main chain of Beta-dextran may be bonded by 1,3, 1,4, or 1,6, and the side chain of Beta-dextran may be bonded by 1,3, 1,4, or 1,6. The dextran in the composition of the contact lens may further include Beta-1-3 / 1-6-D-dextran in Ganoderma lucidum polysaccharide, the main chain of Beta-1-3 / 1-6-D-dextran is bonded by 1,3, and the side chain of Beta-1-3 / 1-6-D-dextran is bonded by 1,6. The extraction sources of dextran in the composition of the contact lens may be yeast, grains, fungi, plants, bacteria, algae, lichens, etc. The yeast as the extraction source of dextran in the composition of the contact lens may be baker's yeast, Saccharomyces cerevisiae. The grains as the extraction source of dextran in the composition of the contact lens may be barley, oats, wheat, rice. The fungi as the extraction source of dextran in the composition of the contact lens may be Ganoderma lucidum, mushrooms, maitake, shiitake, Aspergillus niger. The plants as the extraction source of dextran in the composition of the contact lens may be aloe vera, Echinacea.

[0039] The molecular weight of dextran in the composition of the contact lens described in this disclosure refers to the number-average molecular weight of the overall dextran in the contact lens, and its formula is: (Σ molecular weight of dextran in the composition of the contact lens) / total number of molecules.

[0040] The molecular particle size of dextran in the composition of the contact lens described in this disclosure refers to the median molecular diameter of the overall dextran in the composition of the contact lens.

[0041] The types of contact lenses described in this disclosure may be hydrogel contact lenses or silicone hydrogel contact lenses. Hydrogel contact lenses contain hydrogel monomers. Silicone hydrogel contact lenses contain silicone hydrogel monomers. The main monomer of the contact lens refers to the monomer component with the highest weight percentage in the contact lens.

[0042] The hydrogel monomers of the contact lenses described in the present disclosure may include 2-hydroxyethyl methacrylate (HEMA), methacrylic acid (MAA), glycerol monomethacrylate (GMA), N-vinyl-2-pyrrolidinone (NVP), methyl methacrylate (MMA), N,N-dimethyl acrylamide (DMAA), glucan, and the like.

[0043] The hydrogels of the contact lenses described in the present disclosure may be, but are not limited to, contact lens materials classified by the US Food and Drug Administration (USFDA) into Group 1, i.e., nonionic polymers with low water content (less than 50 weight percent), such as Helfilcon A&B, Hioxifilcon B, Mafilcon, Polymacon, Tefilcon, Tetrafilcon A, etc. Alternatively, the aforementioned hydrogels may be contact lens materials classified by the USFDA into Group 2, i.e., nonionic polymers with high water content (greater than 50 weight percent), such as Acofilcon A, Alfafilcon A, Hilafilcon B, Hioxifilcon A, Hioxifilcon B, Hioxifilcon D, Nelfilcon A, Nesofilcon A, Omafilcon A, and Samfilcon A, etc. Alternatively, the aforementioned hydrogels may be contact lens materials classified by the USFDA into Group 3, i.e., ionic polymers with low water content (less than 50 weight percent), such as Deltafilcon A, etc. Alternatively, the aforementioned hydrogels may be contact lens materials classified by the USFDA into Group 4, i.e., ionic polymers with high water content (greater than 50 weight percent), such as Etafilcon A, Focofilcon A, Methafilcon A, Methafilcon B, Ocufilcon A, Ocufilcon B, Ocufilcon C, Ocufilcon D, Ocufilcon E, Phemfilcon A, Vifilcon A, etc.

[0044] The silicone hydrogel monomers of the contact lenses described in the present disclosure may be, but are not limited to, 2-hydroxyethyl methacrylate, glycerolmonomethacrylate, methacrylic acid, 3-methacryloyloxypropyltris(trimethylsilyloxy)silane, N-vinyl-2-pyrrolidinone, N,N-dimethyl acrylamide, (3-methacryloxy-2-hydroxypropoxy)propylbis(trimethylsiloxy)methylsilane, or (3-acryloxy-2-hydroxypropoxypropyl)terminated polydimethylsiloxane.

[0045] The silicone hydrogels of the contact lenses described in the present disclosure may be, but are not limited to, contact lens materials classified into Group 5 by the US Food and Drug Administration, such as Balafilcon A, Comfilcon A, Efrofilcon A, Enfilcon A, Galyfilcon A, Lotrafilcon A, Lotrafilcon B, Narafilcon A, Narafilcon B, Senofilcon A, Delefilcon A, Somofilcon A, etc.

[0046] The initiators of the contact lenses described in the present disclosure may be, but are not limited to, 2-hydroxy-2-methyl-propiophenone.

[0047] The crosslinking agents of the contact lenses described in the present disclosure may be, but are not limited to, ethylene glycol dimethacrylate or 1,1,1-trimethylol propane trimethacrylate.

[0048] The diluent of the contact lens described in the present disclosure may be polyethylene glycol 300, polyethylene glycol 600, polyethylene glycol 800, polyethylene glycol 1000, polyethylene glycol 2000, polyethylene glycol 4000, 1,4 - butanediol, ethanol, isopropyl alcohol, glycerol, or 1 - hexanol.

[0049] The ultraviolet (UV) absorber of the contact lens described in the present disclosure may be, but is not limited to, 2 - [3 - (2H - benzotriazol - 2 - yl) - 4 - hydroxyphenyl]ethyl methacrylate, 4 - methacryloxy - 2 - hydroxybenzophenone, 2 - phenylethylacrylate, 2 - phenylethyl methacrylate, 2 - [2 - hydroxy - 5 - [2 - (methacryloxy)ethyl]phenyl] - 2H - benzotriazole, or 2 - (4 - benzoyl - 3 - hydroxyphenoxy)ethyl acrylate.

[0050] The blue light absorber of the contact lens described in the present disclosure may be, but is not limited to, 4 - (phenyldiazenyl)phenyl methacrylate.

[0051] The pigments of the contact lenses described in the present disclosure may include anthocyanidin, beta-carotene, curcumin, luciferin, lutein, lycopene, phycobillin, phycoerythrin, phycocyanin, riboflavin (vitamin B2), zeaxanthin, photochromic dyes, thermochromic dyes, etc., and their derivatives.

[0052] The beneficial agents of the contact lenses described in the present disclosure may include antibiotics, bacteriostatic agents, antiviral agents, antifungal drugs, antiallergic agents, apomorphine, bromocriptine, dopamine receptor agonists, levodopa, quinpirole, steroids, non-steroidal anti-inflammatory drugs (NSAIDs), surfactants, miotics, enzyme inhibitors, anaesthetics, vasoconstrictors, nutrients, etc.

[0053] The antioxidants of the contact lenses described in the present disclosure may be vitamin A, vitamin C, vitamin E, uric acid, carotenoid, flavonoids, resveratrol, selenomethionine, etc.

[0054] The myopia control agent of the contact lens described in the present disclosure may include cycloplegic agents, mydriatic agents (mydriatics), selective / non-selective muscarinic receptor antagonists, etc., which have the effect of controlling, slowing down, delaying or preventing the progression of myopia. For example, by blocking the M-type muscarinic receptors of the parasympathetic nerve, the ciliary muscle that controls the pupil can be relaxed and paralyzed, and then the pupil can be dilated. Such as atropine ((3-endo)-8-Methyl-8-azabicyclo[3.2.1]oct-3-yltropate), atropine sulphate, cyclopentolate (2-(Dimethylamino)ethyl(1-hydroxycyclopentyl)(phenyl)acetate), cyclopentolate HCl, eucatropine (1,2,2,6-Tetramethyl-4-piperidinylhydroxy(phenyl)acetate), homatropine ((3-endo)-8-Methyl-8-azabicyclo[3.2.1]oct-3-ylhydroxy(phenyl)acetate), nuvenzepine, phenylephrine HCl, pirenzepine, raceanisodamine, rispenzepine, scopolamine ((1R,2R,4S,5S,7s)-9-Methyl-3-oxa-9-azatricyclo[3.3.1.02,4]non-7-yl(2S)-3-hydroxy-2-phenylpropanoate), scopolamine HBr, telenzepine, tropicamide (N-Ethyl-3-hydroxy-2-phenyl-N-(4-pyridinylmethyl)propanamide), etc., and their salts.

[0055] The structural composition of the contact lenses described in this disclosure can be a single-layer lens or at least a two-layer lens. The colored contact lenses can be composed of two layers, such as a lens body layer and a color layer. The colored contact lenses can be composed of three layers, such as a lens body layer, a color layer, and an anti-shedding protective layer. The colored contact lenses can be composed of four layers, such as a lens body layer, a first color layer, a second color layer, and an anti-shedding protective layer. The colored contact lenses can be composed of five layers, such as a lens body layer, a first color layer, a second color layer, a third color layer, and an anti-shedding protective layer. The colored contact lenses can be composed of another five layers, such as a lens body layer, a first color layer, a separation layer, a second color layer, and an anti-shedding protective layer.

[0056] The stable structure of the contact lenses described in this disclosure can have a rotational stability design, such as a lower-thickening and weight-dropping design, a balance design with thickening on both sides, an asymmetric balance design, and an upper-and-lower thinning stability design, etc.

[0057] The functions of the contact lenses described in this disclosure can be myopia correction, hyperopia correction, presbyopia correction, astigmatism correction, myopia control and delay, corneal reshaping, etc.

[0058] The average transmittance of the contact lenses described in this disclosure refers to the average value of the respective transmittances taken at each integer wavelength interval of 1 nm. The average transmittance from 400 nm to 700 nm is the average value of the transmittances at each 1 nm wavelength interval from 400 nm to 700 nm, that is, the average value of the transmittances at 400 nm, 401 nm, 402 nm, 403 nm, and so on up to 700 nm. The average transmittance from 450 nm to 630 nm is the average value of the transmittances at each 1 nm wavelength interval from 450 nm to 630 nm, that is, the average value of the transmittances at 450 nm, 451 nm, 452 nm, 453 nm, and so on up to 630 nm.

[0059] The water content of the contact lenses described in this disclosure is calculated by hydrating the contact lenses with pure water according to ISO 18369-4 (2017), and calculating the water content based on the weights of the contact lenses before and after hydration. The formula is as follows: Water content = (weight after hydration - weight before hydration) / weight after hydration. The water content of the contact lenses is affected by the type of buffer solution used for soaking. Therefore, the contact lenses will be soaked in the buffer solution for at least 24 hours before measurement.

[0060] The oxygen permeability of the contact lens described in the present disclosure is calculated by hydrating the contact lens with pure water according to ISO 18369-4 (2017). The oxygen permeability of the contact lens is affected by the type of buffer solution in which it is immersed, so the contact lens is immersed in the buffer solution for at least 24 hours before measurement.

[0061] The buffer solution described in the present disclosure may contain at least one, at least two, at least three, and at least four humectants. The buffer solution may contain at least one, at least two, at least three, and at least four cooling agents. The buffer solution may contain at least one, at least two, at least three, and at least four eye care ingredients. The buffer solution may contain at least one, at least two, at least three, and at least four buffers. The buffer solution may contain at least one, at least two, at least three, and at least four antibacterial agents. The buffer solution may contain at least one, at least two, at least three, and at least four antioxidants. The buffer solution may contain at least one, at least two, at least three, and at least four chelating agents. The buffer solution may contain at least one, at least two, at least three, and at least four surfactants.

[0062] The humectants of the buffer solution described in the present disclosure may include glucan, polyethylene glycol-40 hydrogenated castor oil (PEG 40 Castor Oil), polyethylene glycol-400 (PEG 400), glycerol, allantoin, hyaluronic acid, ceramide, cholesterol, seabuckthorn oil, polyglutamic acid (γ-PGA), trehalose, alginic acid, hydroxypropyl methylcellulose (HPMC), 2-methacryloyloxyethyl phosphorylcholine (MPC; 2-Methacryloyloxyphosphorylcholine), etc., and their salts.

[0063] The steric configuration of dextran in the buffer solution described in this disclosure can be D-form or L-form. Dextran can include Alpha-dextran and Beta-dextran. Alpha-dextran can include Alpha-1-3-dextran, Alpha-1-4-dextran, Alpha-1-6-dextran, Alpha-1-3 / 1-4-dextran, Alpha-1-4 / 1-6-dextran, and Alpha-1-3 / 1-6-dextran, where the main chain of Alpha-dextran can be 1,3-bonded, 1,4-bonded, or 1,6-bonded, and the side chain of Alpha-dextran can be 1,3-bonded, 1,4-bonded, or 1,6-bonded. Beta-dextran can include Beta-1-3-dextran, Beta-1-4-dextran, Beta-1-6-dextran, Beta-1-3 / 1-4-dextran, Beta-1-4 / 1-6-dextran, and Beta-1-3 / 1-6-dextran, where the main chain of Beta-dextran can be 1,3-bonded, 1,4-bonded, or 1,6-bonded, and the side chain of Beta-dextran can be 1,3-bonded, 1,4-bonded, or 1,6-bonded. The dextran in the buffer solution can further include Beta-1-3 / 1-6-D-dextran in Ganoderma polysaccharide, where the main chain of Beta-1-3 / 1-6-D-dextran is 1,3-bonded and the side chain of Beta-1-3 / 1-6-D-dextran is 1,6-bonded. The extraction sources of dextran in the buffer solution can be yeast, grains, fungi, plants, bacteria, algae, lichens, etc. The yeast as the extraction source of dextran in the buffer solution can be baker's yeast, Saccharomyces cerevisiae. The grains as the extraction source of dextran in the buffer solution can be barley, oats, wheat, rice. The fungi as the extraction source of dextran in the buffer solution can be Ganoderma lucidum, mushrooms, maitake, shiitake, Aspergillus niger. The plants as the extraction source of dextran in the buffer solution can be aloe vera, Echinacea.

[0064] The molecular weight of dextran in the buffer solution described in this disclosure refers to the number-average molecular weight of the overall dextran in the buffer solution, and its formula is: (Σ molecular weight of dextran in the buffer solution) / total number of molecules.

[0065] The molecular particle size of dextran in the buffer solution described in this disclosure refers to the median molecular diameter of the overall dextran in the buffer solution.

[0066] The cooling agent of the buffer solution described in the present disclosure has the effect of making the acting site feel cool. The cooling agent may include menthol, 2-Isopropyl-N,2,3-trimethylbutyramide (WS-23), N-Ethyl-p-menthane-3-carboxamide (WS-3), Ethyl 3-(p-menthane-3-carboxamido)acetate (WS-5), (1R,2S,5R)-N-(4-Methoxyphenyl)-p-menthanecarboxamide (WS-12), N-Ethyl-2,2-diisopropylbutanamide (WS-27), N-(1,1-Dimethyl-2-hydroxyethyl)-2,2-diethylbutanamide (WS-116), etc., and their salts.

[0067] The eye care components of the buffer solution described in the present disclosure may include vitamin A, lutein, omega-3 fatty acid, anthocyanin, astaxanthin, carotene, bilberry extract, lecithin, or a combination of the foregoing.

[0068] The buffer of the buffer solution described in the present disclosure may be buffer salts, such as: citrate, acetate, phosphate, borate, sulfate, carbonate, nitrate, chloride, or a combination of the foregoing salts. The cations of the buffer salts may be sodium, potassium, magnesium, calcium. The buffer may be more preferably N-[Tris(hydroxymethyl)methyl]-3-aminopropanesulfonic acid (TAPS), N,N-Bis(2-hydroxyethyl)glycine (Bicine), Tris(hydroxymethyl)aminomethane (Tris), N-Tris(hydroxymethyl)methylglycine (Tricine), 4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid hemisodium salt (HEPES), N-Tris(hydroxymethyl)methyl-2-aminoethanesulfonic acid (TES), 3-(N-Morpholino)ethanesulfonic acid (MOPS), Piperazine-N,N'-bis(2-ethanesulfonic acid) (PIPES), Cacodylate, 2-Morpholinoethanesulfonic acid (MES), etc., and their salts. Ethyl 3-(p-menthane-3-carboxamido)acetate (WS-5), (1R,2S,5R)-N-(4-Methoxyphenyl)-p-menthanecarboxamide (WS-12), N-Ethyl-2,2-diisopropylbutanamide (WS-27), N-(1,1-Dimethyl-2-hydroxyethyl)-2,2-diethylbutanamide (WS-116), etc., and their salts. -N,N'-bis(2-ethanesulfonic acid) (PIPES), Cacodylate, 2-Morpholinoethanesulfonic acid (MES), etc., and their salts.

[0069] The antibacterial agents of the buffer solution described in this disclosure may include benzoic acid, sodium nitrite, calcium propionate, boric acid, sodium borate, methylparaben, DMDM hydantoin (DMDMH), silver ions (Ag + ), polyhexamethylene biguanide (PHMB), etc., and their salts.

[0070] The antioxidants of the buffer solution described in this disclosure may include vitamin A, vitamin B, vitamin C, vitamin D, vitamin E, oxidized or reduced coenzyme Q10, glutathione, lipoic acid, carotenoids, lutein, butylated hydroxytoluene (BHT), butylated hydroxyanisole (BHA), propyl gallate (PG), tertiary butyl hydroquinone (TBHQ), etc., and their salts.

[0071] The chelating agents of the buffer solution described in this disclosure may include ethylenediamine (en), 2,2'-bipyridine (bipy), 1,10-phenanthroline (phen), oxalate (oxalic acid), ethylenediaminetetraacetic acid (EDTA), 1,2-bis(dimethylarsino)benzene (diars), etc., and their salts.

[0072] The surfactants of the buffer solution described in this disclosure may include poloxamer 407 (KP407), sodium dodecyl sulfate (SDS), cetyltrimethylammonium bromide (CTAB), stearyltrimethylammonium chloride (STAC), potassium stearate, gum arabic, sodium alginate, etc., and their salts.

[0073] The viscosity of the buffer solution described in this disclosure refers to the viscosity of the buffer solution, which can represent the fluidity of the buffer solution. The viscosity is measured using a viscometer or a micro-viscometer. The rotating shaft can be selected according to the measurement volume and rotation speed. The measurement rotation speed can be selected from 0.01 rpm to 500 rpm, and the measurement volume is at least 1 mL or more. The measurement details follow the operation manual of the viscometer used.

[0074] The buffer solution described in this disclosure can be used as a preservative solution for contact lens products, and can also be used in eye wash solutions, moisturizing solutions, eye drops, eye medications, and contact lens cleaning solutions.

[0075] The contact lens product described in the present disclosure may be composed of a contact lens body, a buffer solution, and a package. The contact lens body will be immersed in the buffer solution. The term "contact lens" in the present disclosure refers to the contact lens body. The contact lens body and the solution may contain a humectant, a monomer, a UV absorber, a blue absorber, beneficial agents, a dye, a myopia control agent, a salt of a weak acid and its conjugate base, a salt of a weak base and its conjugate acid, an anionic agent, a cationic agent, and other beneficial agents. The package described in the present disclosure may be made by combining a plastic container and an aluminum foil lid. The plastic container may be made of polypropylene (PP), polystyrene (PS), polyethylene terephthalate (PET), or other plastic materials, and biodegradable plastics may also be used, such as those containing polylactic acid (PLA), polyhydroxyalkanoates (PHA), or other decomposable plastics. The biodegradable plastics may also be mixed with biodegradable plasticizers to achieve modification or modification effects. The aluminum foil lid in the present disclosure may be made of a composite aluminum foil material with a plastic coating.

[0076] Unless otherwise noted, the measurement environment described in the present disclosure is a temperature of 25°C and a humidity of 50%.

[0077] According to the above embodiments, specific examples are presented below for detailed description.

[0078] <First Comparative Example>

[0079] The contact lens product in the first comparative example includes a contact lens and a buffer solution, and the contact lens is immersed in the buffer solution.

[0080] The contact lens in the first comparative example is a hydrogel contact lens, and its main monomer is hydroxyethyl methacrylate. The composition of the contact lens contains a humectant, and the buffer solution contains a humectant, but neither the humectant in the composition of the contact lens nor the humectant in the buffer solution contains dextran.

[0081] The contact lens of the first comparative example is a hydrogel contact lens, the main monomer of which is 2-hydroxyethyl methacrylate, and the water content of the contact lens is Cw, and Cw = 54.07%.

[0082] <The First Embodiment>

[0083] The contact lens product of the first embodiment includes a contact lens and a buffer solution, and the contact lens is immersed in the buffer solution.

[0084] The contact lens of the first embodiment is a hydrogel contact lens, the main monomer of which is 2-hydroxyethyl methacrylate. The composition of the contact lens contains a humectant, and the buffer solution contains a humectant, wherein the humectant in the composition of the contact lens contains dextran, and the humectant in the buffer solution does not contain dextran.

[0085] Please refer to Table 1, which presents the details of the components and parameters of the contact lens and the buffer solution in the contact lens product of the first embodiment, where Pc is the weight percentage of dextran in the composition of the contact lens, MWc is the molecular weight of dextran in the composition of the contact lens, PSc is the molecular particle size of dextran in the composition of the contact lens, Cw is the water content of the contact lens, Dc is the diameter of the contact lens, T4070 is the average transmittance of the contact lens at 400 nm to 700 nm, T4563 is the average transmittance of the contact lens at 450 nm to 630 nm, Pb is the weight percentage of dextran in the buffer solution, MWb is the molecular weight of dextran in the buffer solution, PSb is the molecular particle size of dextran in the buffer solution, VI is the viscosity of the buffer solution, pHb is the pH value of the buffer solution, and Ob is the osmotic pressure of the buffer solution.

[0086]

[0087]

[0088] The parameter definitions of the following embodiments are the same as those in Table 1 of the first embodiment, so they will not be elaborated hereinafter.

[0089] <The Second Embodiment>

[0090] The contact lens product of the second embodiment includes a contact lens and a buffer solution, and the contact lens is immersed in the buffer solution.

[0091] The contact lens of the second embodiment is a hydrogel contact lens, the main monomer of which is 2-hydroxyethyl methacrylate. The composition of the contact lens contains a humectant, and the buffer solution contains a humectant, wherein the humectant in the composition of the contact lens contains dextran, and the humectant in the buffer solution does not contain dextran.

[0092] Please refer to Table 2, which presents the details of the components and parameters of the contact lens and the buffer solution in the contact lens product of the second embodiment.

[0093]

[0094] <Third Embodiment>

[0095] The contact lens product of the third embodiment includes a contact lens and a buffer solution, and the contact lens is immersed in the buffer solution.

[0096] The contact lens of the third embodiment is a hydrogel contact lens, and its main monomer is 2-hydroxyethyl methacrylate. The composition of the contact lens contains a humectant, and the buffer solution contains a humectant. Among them, the humectant in the composition of the contact lens does not contain dextran, and the humectant in the buffer solution contains dextran.

[0097] Please refer to Table 3, which presents the details of the components and parameters of the contact lens and the buffer solution in the contact lens product of the third embodiment.

[0098]

[0099] <Fourth Embodiment>

[0100] The contact lens product of the fourth embodiment includes a contact lens and a buffer solution, and the contact lens is immersed in the buffer solution.

[0101] The contact lens of the fourth embodiment is a hydrogel contact lens, and its main monomer is 2-hydroxyethyl methacrylate. The composition of the contact lens contains a humectant, and the buffer solution contains a humectant. Among them, both the humectant in the composition of the contact lens and the humectant in the buffer solution contain dextran.

[0102] Please refer to Table 4, which presents the details of the components and parameters of the contact lens and the buffer solution in the contact lens product of the fourth embodiment.

[0103]

[0104] <Fifth Embodiment>

[0105] The contact lens product of the fifth embodiment includes a contact lens and a buffer solution, and the contact lens is immersed in the buffer solution.

[0106] The contact lens of the fifth embodiment is a hydrogel contact lens, and its main monomer is 2-hydroxyethyl methacrylate. The composition of the contact lens contains a humectant, and the buffer solution contains a humectant. Among them, both the humectant in the composition of the contact lens and the humectant in the buffer solution contain dextran.

[0107] Please refer to Table 5, which presents the composition and parameter details of the contact lens and the buffer solution in the contact lens product of the fifth embodiment.

[0108]

[0109] Although the present disclosure has been disclosed as above in embodiments, it is not intended to limit the present disclosure. Any person skilled in the art can make various changes and modifications without departing from the spirit and scope of the present disclosure. Therefore, the protection scope of the present disclosure shall be subject to that defined by the appended claims.

Claims

1. A contact lens, characterized in that: The composition of the contact lens comprises: A moisturizing agent comprising a glucan, wherein the glucan in the contact lens composition comprises 1-3 / 1-6-glucan; The weight percentage of the dextran in the composition of the contact lens is Pc, and the average transmittance of the contact lens at 400nm to 700nm is T4070, which meets the following conditions: 0.001% ≤ Pc ≤ 1.00%; and 90％≤T4070。 2. The contact lens according to claim 1, wherein The weight percentage of the dextran in the composition of the contact lens is Pc, which satisfies the following conditions: 0.003%≤Pc≤0.10%.

3. The contact lens according to claim 1, wherein The molecular weight of the dextran in the composition of the contact lens is MWc, which satisfies the following conditions: 10kDa≤MWc≤2000kDa.

4. The contact lens according to claim 1, wherein The molecular particle size of the dextran in the composition of the contact lens is PSc, which satisfies the following conditions: 50nm≤PSc≤5000nm.

5. The contact lens according to claim 1, wherein The diameter of the contact lens is Dc, which satisfies the following conditions: 13.8mm≤Dc≤14.5mm.

6. The contact lens according to claim 5, wherein: The contact lens is a hydrogel contact lens, and a main monomer of the contact lens is hydroxyethyl methacrylate.

7. The contact lens according to claim 6, wherein: The composition of the contact lens further comprises: an ultraviolet light absorber or a blue light absorber; a pigment; A beneficial agent; an antioxidant; and A myopia control agent.

8. A contact lens product, characterized in that: Include: The contact lens of claim 1; and A buffer solution in which the contact lens is immersed.

9. The contact lens product according to claim 8, characterized in that: The buffer solution contains a humectant, the humectant in the buffer solution contains a glucan, and the glucan in the buffer solution contains Beta-glucan; Wherein, the weight percentage of the dextran in the buffer solution is Pb, which satisfies the following conditions: 0.0003%≤Pb≤1.00%.

10. The contact lens product according to claim 9, characterized in that: The molecular weight of the dextran in the buffer solution is MWb, which satisfies the following conditions: 50kDa≤MWb≤1500kDa.

11. The contact lens product according to claim 10, characterized in that: The molecular particle size of the dextran in the buffer solution is PSb, which satisfies the following conditions: 500nm≤PSb≤4000nm.

12. The contact lens product according to claim 11, characterized in that: The water content of the contact lens is Cw, which satisfies the following conditions: 54.5%≤Cw.

13. A contact lens, characterized in that: The composition of the contact lens comprises: A moisturizing agent comprising a glucan, wherein the glucan in the contact lens composition comprises beta-glucan; The weight percentage of the dextran in the composition of the contact lens is Pc, and the average transmittance of the contact lens from 450nm to 630nm is T4563, which meets the following conditions: 0.0001% ≤ Pc; and 90％≤T4563。 14. The contact lens according to claim 13, wherein The Beta-glucan in the contact lens composition comprises 1-3 / 1-6-glucan.

15. The contact lens according to claim 14, wherein The weight percentage of the dextran in the composition of the contact lens is Pc, which satisfies the following conditions: 0.0005%≤Pc≤5.00%.

16. The contact lens according to claim 15, wherein The molecular weight of the dextran in the composition of the contact lens is MWc, which satisfies the following conditions: 30kDa≤MWc≤1800kDa.

17. The contact lens according to claim 16, wherein: The molecular particle size of the dextran in the composition of the contact lens is PSc, which satisfies the following conditions: 500nm≤PSc≤4000nm.

18. A contact lens product, characterized in that: Include: The contact lens of claim 13.

19. A contact lens product, characterized in that: Include: a contact lens; and a buffer solution in which the contact lens is immersed; The buffer solution comprises a humectant, the humectant in the buffer solution comprises a glucan, and the glucan in the buffer solution comprises Beta-glucan; Wherein, the weight percentage of the dextran in the buffer solution is Pb, which satisfies the following conditions: 0.0001%≤Pb≤5.00%.

20. The contact lens product according to claim 19, characterized in that: The weight percentage of the dextran in the buffer solution is Pb, which satisfies the following conditions: 0.001%≤Pb≤0.30%.

21. The contact lens product according to claim 20, characterized in that: The Beta-glucan in the buffer solution contains 1-3 / 1-6-glucan.

22. The contact lens product according to claim 19, characterized in that: The contact lens composition includes a humectant, and the humectant includes Beta-glucan.

23. The contact lens product according to claim 19, characterized in that: The molecular weight of the dextran in the buffer solution is MWb, which satisfies the following conditions: 10kDa≤MWb≤2000kDa.

24. The contact lens product according to claim 23, characterized in that: The molecular particle size of the dextran in the buffer solution is PSb, which satisfies the following conditions: 50nm≤PSb≤5000nm.

25. The contact lens product according to claim 24, characterized in that: The viscosity of the buffer solution is VI, which satisfies the following conditions: VI≤10Pa·s.

26. The contact lens product according to claim 25, characterized in that: The pH value of the buffer solution is pHb, which satisfies the following conditions: 7.3≤pHb≤7.

5.

27. The contact lens product according to claim 26, characterized in that: The osmotic pressure of the buffer solution is Ob, which satisfies the following conditions: 0.280Osmol / kg·H2O≤Ob≤0.350Osmol / kg·H2O.

28. The contact lens product according to claim 19, characterized in that: The contact lens composition comprises a humectant, and the humectant comprises dextran; and The weight percentage of the dextran in the composition of the contact lens is Pc, the average transmittance of the contact lens at 400nm to 700nm is T4070, the average transmittance of the contact lens at 450nm to 630nm is T4563, the molecular weight of the dextran in the composition of the contact lens is MWc, the molecular particle size of the dextran in the composition of the contact lens is PSc, the diameter of the contact lens is Dc, the weight percentage of the dextran in the buffer solution is Pb, the molecular weight of the dextran in the buffer solution is MWb, the molecular particle size of the dextran in the buffer solution is PSb, the viscosity of the buffer solution is VI, the pH value of the buffer solution is pHb, and the osmotic pressure of the buffer solution is Ob, which meets the following conditions: 0.008%≤Pc≤0.013%; 92.5％≤T4070； 92.5％≤T4563； 150kDa≤MWc≤700kDa; 1600nm≤PSc≤2100nm; 14.0mm≤Dc≤14.2mm; 0.0055%≤Pb≤0.008%; 150kDa≤MWb≤700kDa; 1600nm≤PSb≤2100nm; 0.9Pa·s≤VI≤1.1Pa·s; 7.35 ≤ pHb ≤ 7.45; and 0.295Osmol / kg·H2O≤Ob≤0.305Osmol / kg·H2O。

Images